Gilead Sciences Inc (GILD)
$92.38 $0.37 (0.40%) 2:43 AM 12/12/24
NASDAQ | $USD | Drug Manufacturers - GeneralStock Data
-
Market Cap
$114.82B -
Day's Range
$92.03 - $94.65 -
Volume
6,506,967 -
52 Week Low / High
$60.75 - $98.90 -
PE Ratio
1,023.67x -
PEG Ratio
0.53 -
Dividend Frequency
quarterly
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
- 14
- Strong Buy
- 5
- Buy
- 14
- Hold
- 0
- Sell
- 0
- Strong Sell
- $85.47
- Target Price
Company News
-
Gilead Sprints To A Profit-Taking Zone After Riding Covid Drug To Beat And Raise — Nov 7th, 2024
Gilead stock sprinted to a profit-taking zone Thursday after Gilead Sciences rode its Covid treatment to another beat and raise. Continue reading View comments...
-
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...
-
Gilead Sprints To A Profit-Taking Zone After Riding Covid Drug To Beat And Raise — Nov 7th, 2024
Gilead stock sprinted to a profit-taking zone Thursday after Gilead Sciences rode its Covid treatment to another beat and raise. Continue reading View comments...
-
Gilead Sprints To A Profit-Taking Zone After Riding Covid Drug To Beat And Raise — Nov 7th, 2024
Gilead stock sprinted to a profit-taking zone Thursday after Gilead Sciences rode its Covid treatment to another beat and raise. Continue reading View comments...
-
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...
-
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...
-
Gilead Sciences Rides Covid Treatment To Another Beat And Raise — Nov 6th, 2024
Gilead Sciences rode its Covid treatment to a third-quarter beat and raise late Wednesday, and Gilead stock popped. Continue reading View comments...
-
Gilead Sprints To A Profit-Taking Zone After Riding Covid Drug To Beat And Raise — Nov 7th, 2024
Gilead stock sprinted to a profit-taking zone Thursday after Gilead Sciences rode its Covid treatment to another beat and raise. Continue reading View comments...
-
Gilead Sprints To A Profit-Taking Zone After Riding Covid Drug To Beat And Raise — Nov 7th, 2024
Gilead stock sprinted to a profit-taking zone Thursday after Gilead Sciences rode its Covid treatment to another beat and raise. Continue reading View comments...
-
Gilead Sciences Rides Covid Treatment To Another Beat And Raise — Nov 6th, 2024
Gilead Sciences rode its Covid treatment to a third-quarter beat and raise late Wednesday, and Gilead stock popped. Continue reading View comments...
-
Gilead Sciences Rides Covid Treatment To Another Beat And Raise — Nov 6th, 2024
Gilead Sciences rode its Covid treatment to a third-quarter beat and raise late Wednesday, and Gilead stock popped. Continue reading View comments...
-
Gilead Sprints To A Profit-Taking Zone After Riding Covid Drug To Beat And Raise — Nov 7th, 2024
Gilead stock sprinted to a profit-taking zone Thursday after Gilead Sciences rode its Covid treatment to another beat and raise. Continue reading View comments...
-
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...
-
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...
-
Gilead Sciences Rides Covid Treatment To Another Beat And Raise — Nov 6th, 2024
Gilead Sciences rode its Covid treatment to a third-quarter beat and raise late Wednesday, and Gilead stock popped. Continue reading View comments...
-
Gilead Sprints To A Profit-Taking Zone After Riding Covid Drug To Beat And Raise — Nov 7th, 2024
Gilead stock sprinted to a profit-taking zone Thursday after Gilead Sciences rode its Covid treatment to another beat and raise. Continue reading View comments...
-
Gilead Sciences Rides Covid Treatment To Another Beat And Raise — Nov 6th, 2024
Gilead Sciences rode its Covid treatment to a third-quarter beat and raise late Wednesday, and Gilead stock popped. Continue reading View comments...
-
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...
-
Gilead Sciences Rides Covid Treatment To Another Beat And Raise — Nov 6th, 2024
Gilead Sciences rode its Covid treatment to a third-quarter beat and raise late Wednesday, and Gilead stock popped. Continue reading View comments...
-
Gilead Sprints To A Profit-Taking Zone After Riding Covid Drug To Beat And Raise — Nov 7th, 2024
Gilead stock sprinted to a profit-taking zone Thursday after Gilead Sciences rode its Covid treatment to another beat and raise. Continue reading View comments...
-
Goldman Sachs: Gilead Sciences, Inc. (NASDAQ:GILD) Is A Stock With High Consensus ROE — Oct 19th, 2024
We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this piece, we will look at where Gilead Sciences, Inc. (NASDAQ:GILD) ranks in the list. As the fourth quarter of 2024 settles in, the narrative surrounding stocks on...
-
Gilead Sprints To A Profit-Taking Zone After Riding Covid Drug To Beat And Raise — Nov 7th, 2024
Gilead stock sprinted to a profit-taking zone Thursday after Gilead Sciences rode its Covid treatment to another beat and raise. Continue reading View comments...
-
Gilead Sciences Rides Covid Treatment To Another Beat And Raise — Nov 6th, 2024
Gilead Sciences rode its Covid treatment to a third-quarter beat and raise late Wednesday, and Gilead stock popped. Continue reading View comments...
-
Gilead Sciences Rides Covid Treatment To Another Beat And Raise — Nov 6th, 2024
Gilead Sciences rode its Covid treatment to a third-quarter beat and raise late Wednesday, and Gilead stock popped. Continue reading View comments...
-
Gilead Sprints To A Profit-Taking Zone After Riding Covid Drug To Beat And Raise — Nov 7th, 2024
Gilead stock sprinted to a profit-taking zone Thursday after Gilead Sciences rode its Covid treatment to another beat and raise. Continue reading View comments...
-
Gilead Sciences Rides Covid Treatment To Another Beat And Raise — Nov 6th, 2024
Gilead Sciences rode its Covid treatment to a third-quarter beat and raise late Wednesday, and Gilead stock popped. Continue reading View comments...
-
Gilead Sciences Rides Covid Treatment To Another Beat And Raise — Nov 6th, 2024
Gilead Sciences rode its Covid treatment to a third-quarter beat and raise late Wednesday, and Gilead stock popped. Continue reading View comments...
-
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...
-
– Novel Investigational Combination Regimen is Advancing to Phase 3 andhas the Potential to Become the First Weekly Oral HIV Treatment – FOSTER CITY, Calif., & RAHWAY, N.J., October 19, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD out...
-
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...
-
Goldman Sachs: Gilead Sciences, Inc. (NASDAQ:GILD) Is A Stock With High Consensus ROE — Oct 19th, 2024
We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this piece, we will look at where Gilead Sciences, Inc. (NASDAQ:GILD) ranks in the list. As the fourth quarter of 2024 settles in, the narrative surrounding stocks on...
-
Gilead Sciences Rides Covid Treatment To Another Beat And Raise — Nov 6th, 2024
Gilead Sciences rode its Covid treatment to a third-quarter beat and raise late Wednesday, and Gilead stock popped. Continue reading View comments...
-
Gilead Sciences Rides Covid Treatment To Another Beat And Raise — Nov 6th, 2024
Gilead Sciences rode its Covid treatment to a third-quarter beat and raise late Wednesday, and Gilead stock popped. Continue reading View comments...
-
– Novel Investigational Combination Regimen is Advancing to Phase 3 andhas the Potential to Become the First Weekly Oral HIV Treatment – FOSTER CITY, Calif., & RAHWAY, N.J., October 19, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD out...
-
Gilead Sprints To A Profit-Taking Zone After Riding Covid Drug To Beat And Raise — Nov 7th, 2024
Gilead stock sprinted to a profit-taking zone Thursday after Gilead Sciences rode its Covid treatment to another beat and raise. Continue reading View comments...
-
– Novel Investigational Combination Regimen is Advancing to Phase 3 andhas the Potential to Become the First Weekly Oral HIV Treatment – FOSTER CITY, Calif., & RAHWAY, N.J., October 19, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD out...
-
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...
-
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...
-
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead. — Dec 9th, 2024
Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, Carvykti. Continue reading View comments...
-
Goldman Sachs: Gilead Sciences, Inc. (NASDAQ:GILD) Is A Stock With High Consensus ROE — Oct 19th, 2024
We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this piece, we will look at where Gilead Sciences, Inc. (NASDAQ:GILD) ranks in the list. As the fourth quarter of 2024 settles in, the narrative surrounding stocks on...
-
Gilead Sciences Rides Covid Treatment To Another Beat And Raise — Nov 6th, 2024
Gilead Sciences rode its Covid treatment to a third-quarter beat and raise late Wednesday, and Gilead stock popped. Continue reading View comments...
-
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...
-
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead. — Dec 9th, 2024
Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, Carvykti. Continue reading View comments...
-
Gilead Sprints To A Profit-Taking Zone After Riding Covid Drug To Beat And Raise — Nov 7th, 2024
Gilead stock sprinted to a profit-taking zone Thursday after Gilead Sciences rode its Covid treatment to another beat and raise. Continue reading View comments...
-
Gilead Sprints To A Profit-Taking Zone After Riding Covid Drug To Beat And Raise — Nov 7th, 2024
Gilead stock sprinted to a profit-taking zone Thursday after Gilead Sciences rode its Covid treatment to another beat and raise. Continue reading View comments...
-
– Novel Investigational Combination Regimen is Advancing to Phase 3 andhas the Potential to Become the First Weekly Oral HIV Treatment – FOSTER CITY, Calif., & RAHWAY, N.J., October 19, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD out...
-
Gilead Sciences Rides Covid Treatment To Another Beat And Raise — Nov 6th, 2024
Gilead Sciences rode its Covid treatment to a third-quarter beat and raise late Wednesday, and Gilead stock popped. Continue reading View comments...
-
– Novel Investigational Combination Regimen is Advancing to Phase 3 andhas the Potential to Become the First Weekly Oral HIV Treatment – FOSTER CITY, Calif., & RAHWAY, N.J., October 19, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD out...
-
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...
-
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks — Oct 21st, 2024
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir. The data was presented at the ID Week 2024. At 48 weeks, the investigational com...
Portfolio
Comprised of 1 portfolios